BioVector? Multidrug-Resistant Pseudomonas aeruginosa (MDR-PA), a critical pathogen defined by its resistance to multiple antibiotic classes.

• 病原體名稱: 多重耐藥銅綠假單胞菌 (MDR-PA)

• 生物學特征: 革蘭氏陰性桿菌，具有運動性（單極鞭毛），大小約為 0.5-0.8 μm x 1.5-3.0 μm。

• 耐藥定義: 對至少三類抗生素（如氨基糖苷類、碳青霉烯類、頭孢菌素類、氟喹諾酮類等）中的至少一種藥物不敏感。

• 主要耐藥機制:

  • 外排泵: 如 MexAB-OprM 系統(tǒng)的高表達。

  • 外膜通透性降低: 如 OprD 蛋白缺失或表達下調(diào)，導致對碳青霉烯類耐藥。

  • 滅活酶: 產(chǎn)生 β-內(nèi)酰胺酶（如 NDM-1, IMP, VIM 等碳青霉烯酶）。

  
  

• 流行病學: 在中國，MDR-PA 的檢出率呈現(xiàn)上升趨勢，特別是在 ICU 病房。常見的高風險克隆型包括 ST1971, ST244, ST357 等。

• 檢測標準: 遵循 臨床和實驗室標準協(xié)會 (CLSI) 指南進行藥敏試驗。

English Version (英文版)

• Pathogen Name: Multidrug-Resistant Pseudomonas aeruginosa (MDR-PA)

• Biological Characteristics: Gram-negative, motile rod (single polar flagellum), measuring 0.5–0.8 μm by 1.5–3.0 μm.

• MDR Definition: Non-susceptibility to at least one agent in three or more antimicrobial categories (e.g., aminoglycosides, carbapenems, cephalosporins, fluoroquinolones).

• Primary Resistance Mechanisms:

  • Efflux Pumps: Overexpression of systems such as MexAB-OprM.

  • Reduced Permeability: Loss or down-regulation of OprD porins, specifically impacting carbapenem susceptibility.

  • Enzymatic Inactivation: Production of β-lactamases and carbapenemases (e.g., NDM-1, IMP-type, VIM-2).

  
  

• Epidemiology in China: Prevalence has increased over time, notably in ICUs (est. 29.0%). Predominant high-risk clones (HiRiCs) identified in mainland China include ST1971, ST244, and ST357.

• Diagnostic Standards: Susceptibility testing is typically performed using broth micro-dilution methods according to CLSI Guidelines.

Supplier生產(chǎn)廠家:

BioVector NTCC質(zhì)粒載體菌種細胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947

E-mail: [email protected]

工作微信/QQ同號: 1843439339

http://www.nedfriskphoto.com